Armata Pharmaceuticals, Inc. announced on March 25 its financial results for the fourth quarter and full year ended December 31, 2025. The company reported a net loss of $124.3 million for the fourth quarter, or $(3.42) per share on a basic and diluted basis, compared to a net income of $2.6 million in the same period in 2024.
The report is significant as it highlights Armata’s ongoing development efforts in bacteriophage therapeutics aimed at combating antibiotic-resistant bacterial infections—a field considered important due to rising concerns about antibiotic resistance.
According to the company’s statement, grant revenue recognized during the last three months of 2025 was $1.1 million, slightly down from $1.2 million in the prior year’s comparable period due to changes in clinical trial activity for its AP-SA02 program targeting Staphylococcus aureus bacteremia. Research and development expenses decreased to approximately $6.1 million from $8.5 million, attributed mainly to lower clinical trial activity and reduced personnel costs.
General and administrative expenses rose marginally by about $0.1 million compared with the previous year due to higher legal costs but were offset by lower lease expenses. The company also recorded a one-time impairment expense of $5.4 million related to vacated office space in Marina del Rey after adjusting plans for subleasing.
The increase in operating loss was primarily driven by this impairment charge but was partially offset by lower research spending overall during the quarter.
Armata ended December with approximately $14.1 million in cash and equivalents, down from $14.8 million at the end of 2024.
In January 2026, Armata amended several credit agreements with Innoviva Strategic Opportunities LLC extending maturity dates into mid-2027 and aligning warrant expiration dates accordingly.
The company’s audited financial statements include an explanatory paragraph regarding its ability to continue as a going concern under NYSE American Company Guide Sections 401(h) and 610(b).
As described by Armata Pharmaceuticals: “Armata is a late clinical-stage biotechnology company focused on the development of high-purity pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology.” The company said it maintains expertise spanning bench research through clinic trials with manufacturing capabilities designed for eventual commercialization.
Broader implications are reflected by continued industry focus on developing alternatives such as phage therapy amid growing resistance issues globally.
